Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)

نویسندگان

  • Robert K Flamm
  • Leonard R Duncan
  • Dee Shortridge
  • Jennifer I Smart
  • Kamal Hamed
  • Rodrigo E Mendes
  • Helio S Sader
چکیده

Methods. From January 2011 to December 2016, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to annually submit clinical isolates (consecutive, one per patient/infection site) from blood (100), respiratory (100), urine (25), and wound (25) infections. Susceptibility testing was performed using broth microdilution as described by CLSI. MICs were interpreted using CLSI breakpoints, where available. Results. 349 S. maltophilia clinical isolates were obtained as a part of CANWARD (86% from a respiratory source). The susceptibility profile of these isolates is presented below.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.

Against 443 aerobic and anaerobic bacteria isolated from diabetic foot infections, ceftobiprole MICs (microg/ml) at which 90% of the isolates tested were inhibited were as follows: methicillin-resistant Staphylococcus aureus, 1; methicillin-susceptible S. aureus and Staphylococcus lugdunensis, 0.5; Anaerococcus prevotii, 0.125; Finegoldia magna, 0.5; Peptoniphilus asaccharolyticus, 1; Peptostre...

متن کامل

Antimicrobial activity of Ceftaroline and Ceftobiprole tested against MRSA isolates from Turkey, in 2016

Ceftaroline and ceftobiprole are two new cephalosporin molecules on which intense studies have been made for the treatments of bacteria most of which are hospital infection factor, especially resistant gram positive cocci. Ceftaroline which has broad Gram-positive activity recently has been approved for clinical uses by the US Food and Drug Administration. Ceftobiprole has been approved for use...

متن کامل

Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.

Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, including those resistant to oxacillin, as well as against most gram-negative bacilli including Pseudomonas aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 uniqu...

متن کامل

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

Antimicrobial resistance is a global concern. Over the past few years, considerable efforts and resources have been expended to detect, monitor, and understand at the basic level the many different facets of emerging and increasing resistance. Development of new antimicrobial agents has been matched by the development of new mechanisms of resistance by bacteria. Current antibiotics act at a var...

متن کامل

Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

PURPOSE The pharmacology, antimicrobial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of ceftobiprole are reviewed. SUMMARY Ceftobiprole, a novel, broad-spectrum, parenteral cephalosporin, inhibits the cell-wall synthesis of penicillin-binding proteins (PBPs) PBP2a and PBP2x, responsible for the resistance in staphylococci and pneumococci, respe...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 4  شماره 

صفحات  -

تاریخ انتشار 2017